Navigation Links
Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
Date:9/27/2007

NEW YORK, Sept. 27 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb (NYSE: BMY) announced today that Dr. Jeremy Levin has joined the company's Research and Development organization as senior vice president, External Science, Technology and Licensing. He will report to Dr. Elliott Sigal, chief scientific officer and president, Research and Development.

"I am delighted Jeremy has joined our R&D organization at this critical juncture for Bristol-Myers Squibb, as we look to further build our robust pipeline in areas of significant unmet medical need and to transform our pharmaceutical business for the future," said Dr. Sigal. "Jeremy's extensive global network in the pharmaceutical, biotechnology and venture industries will help ensure that we remain a leader in forging creative partnerships to advance the development of novel medicines."

Prior to joining Bristol-Myers Squibb, Dr. Levin served as Global Head of Business Development and Strategic Alliances at the Novartis Institutes of Biomedical Research. In that capacity, he and his team secured hundreds of collaborations in more than 20 countries since 2003. Prior to his tenure at Novartis, Dr. Levin held leadership positions in several biotechnology companies, including Physiome Sciences, Inc. and Cadus Pharmaceutical Corporation. He also was managing director of Perseus Capital LLC, a life sciences venture fund. He has served on the executive committees and boards of several public biosciences companies, as well as the Executive Committee of BIO and the boards of the Biotechnology Institute and the New York Biotechnology Association.

"I am excited about the tremendous opportunity at Bristol-Myers Squibb," said Dr. Levin. "I am especially looking forward to working with Elliott, his team and all the outstanding people at this company. I will look to aggressively complement Bristol-Myers Squibb's world class internal team, capabilities and pipeline with the best science and medicines around the globe."

Dr. Levin received a B.A. (First Class Honors) in Zoology, and M.A. and Doctorate (D.Phil.) in Cell Biology and Chromatin Structure from the University of Oxford, as well as a Medical Degree (MB BChir) from the University of Cambridge. He practiced as a physician in internal medicine in several university hospitals, including Hammersmith Hospital in London. In 2005, Dr. Levin was awarded the Albert Einstein Award for Outstanding Achievement in the Life Sciences.

Bristol-Myers Squibb is a global pharmaceutical and related healthcare products company whose mission is to extend and enhance human life.


'/>"/>
SOURCE Bristol-Myers Squibb
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Ranbaxy joins hand with Cipla to co-market ciprofloxacin
2. Rat joins list of cloned animals
3. Richard Gere Joins Indian Stars For Fight Against AIDS
4. Enbrel Joins with Methotrexate to Cure Rheumatoid Arthritis
5. Anoushka Joins Hands With WFP to Feed the Poor
6. India Joins Hands With Global Body for Vaccine Research
7. Another Statewide Organization Joins the Fight Against Assisted Suicide
8. Two-year-old Joins Mensa, Becomes Its Youngest Ever Genius
9. Senior drug card saves little
10. Reducing Depression In Seniors
11. A sharp increased in senior citizens: set to outpace children.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. ... announced a development collaboration with the Australian critical medicine company, Phebra Pty ... schizophrenia. , LAI medicines can offer improved therapeutic benefits over oral formulations, including ...
(Date:5/5/2016)... (PRWEB) , ... May 05, 2016 , ... ... Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term ... Since first offering the procedure in April of 2015, Florida Hospital Pepin Heart ...
(Date:5/5/2016)... Kansas (PRWEB) , ... May 05, 2016 , ... ... that some macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian ... of red, green, and brown seaweeds. The pair observed that when photosynthetically active ...
(Date:5/5/2016)... ... May 05, 2016 , ... Derrin Doty Group has ... of Bremerton, Port Orchard and communities west of Seattle. The insurance provider’s caring team ... local girl who died suddenly due to complications from the flu, that they have ...
(Date:5/5/2016)... ... May 05, 2016 , ... The University of Western ... host the 2016 National SACA Leadership Conference on the Portland campus September 23-25. ... officers to come together and develop skills to be future leaders in the ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 2016 Research and Markets has announced ... in the USA"  report to their offering.  ,     (Logo: ... the current Positron Emission Tomography (PET) scanner and cyclotron ... market. Along with the current known number of PET ... , the report also contains a detailed breakdown of ...
(Date:5/5/2016)... 5, 2016 ... of the  "Europe Thrombocytopenia Market and ... to their offering.       ... ,The latest research Europe Thrombocytopenia Market ... provides comprehensive insights into Thrombocytopenia pipeline ...
(Date:5/4/2016)... Conn., May 4, 2016  Compass Diversified Holdings (NYSE: ... "Company"), an owner of leading middle market businesses, announced ... ended March 31, 2016. First Quarter 2016 ... and Reinvestment ("CAD" or "Cash Flow") of $13.6 million ... net loss of $15.0 million for the first quarter ...
Breaking Medicine Technology: